Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Synaptogenix Inc
SNPX
Healthcare
Biotechnology
Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD...
), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SNPX)
New Post
View:
Posts & Comments
Threaded Posts
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 02, 2024 6:43am
Synaptogenix, Inc. (NASDAQ:SNPX): Advancing Neurological Tre
https://beyondspx.com/2024/08/01/synaptogenix-inc-nasdaqsnpx-advancing-neurological-treatments-with-bryostatin-1/
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 19, 2023 9:00am
New Press Release - Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patientsNEW YORK, July 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 14, 2023 2:18pm
SNPX ...... big bid just showed up
Smoke & f'king mirrors Whack it ; )
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 14, 2023 2:14pm
SNPX ....just saw this ....it's still alive
Kind of .....Big P & D yesterday...total joke All the Chasers got slaughtered...as usual
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 13, 2023 3:35pm
SNPX.....Don't tell me the last 1/2 hr heroics
is starting Better pump up the volume
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 13, 2023 12:48pm
SNPX .... Now for the rally from sub $1.00....
heading back up to fill thhat gap above $1.25 I'm in sub $1.00 GLT me
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 13, 2023 12:20pm
SNPX ....turned out to be a "spearcatching " game
What a f'king game
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 13, 2023 10:37am
SNPX....Runner on watch list
Trading at $1.55 P.O last year at $7......I'd say people want their money back Needs to break thru $1.80 with volume
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income